- Home
- LVTX vs NTIP Comparison
LVTX vs NTIP Comparison
Compare LVTX & NTIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LVTX
- NTIP
- Stock Information
- Founded
- LVTX 2016
- NTIP 1990
- Country
- LVTX Netherlands
- NTIP United States
- Employees
- LVTX N/A
- NTIP N/A
- Industry
- LVTX Biotechnology: Pharmaceutical Preparations
- NTIP Multi-Sector Companies
- Sector
- LVTX Health Care
- NTIP Miscellaneous
- Exchange
- LVTX Nasdaq
- NTIP Nasdaq
- Market Cap
- LVTX 33.1M
- NTIP 31.9M
- IPO Year
- LVTX 2021
- NTIP 1998
- Fundamental
- Price
- LVTX $1.29
- NTIP $1.24
- Analyst Decision
- LVTX Hold
- NTIP
- Analyst Count
- LVTX 3
- NTIP 0
- Target Price
- LVTX $1.75
- NTIP N/A
- AVG Volume (30 Days)
- LVTX 50.0K
- NTIP 6.5K
- Earning Date
- LVTX 05-14-2025
- NTIP 05-09-2025
- Dividend Yield
- LVTX N/A
- NTIP 8.00%
- EPS Growth
- LVTX N/A
- NTIP N/A
- EPS
- LVTX N/A
- NTIP N/A
- Revenue
- LVTX $4,990,000.00
- NTIP $250,000.00
- Revenue This Year
- LVTX N/A
- NTIP N/A
- Revenue Next Year
- LVTX N/A
- NTIP N/A
- P/E Ratio
- LVTX N/A
- NTIP N/A
- Revenue Growth
- LVTX N/A
- NTIP N/A
- 52 Week Low
- LVTX $0.85
- NTIP $1.17
- 52 Week High
- LVTX $2.53
- NTIP $1.86
- Technical
- Relative Strength Index (RSI)
- LVTX 51.81
- NTIP 47.69
- Support Level
- LVTX $1.18
- NTIP $1.22
- Resistance Level
- LVTX $1.34
- NTIP $1.30
- Average True Range (ATR)
- LVTX 0.08
- NTIP 0.04
- MACD
- LVTX 0.00
- NTIP 0.00
- Stochastic Oscillator
- LVTX 68.75
- NTIP 40.00
About LVTX LAVA Therapeutics N.V.
LAVA Therapeutics NV isa clinical stage immuno-oncology company. It is focused on transforming cancer treatment by developing a platform to selectively induce bispecific antibody utilizing the Gammabody platform for an undisclosed tumor associated antigen for the treatment of cancer. Company's pipeline include's products such as LAVA-1266, LAVA-1427, LAVA-1433, LAVA-1207, PF08046052, JNJ89853413.
About NTIP Network-1 Technologies Inc.
Network-1 Technologies Inc is involved in the business of the development, licensing, and protection of intellectual property assets. The company's current plan includes continuing to pursue licensing opportunities for its intellectual property assets.